Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel: The ATRiBRAVE Trial

NCT05582538 is registered in ClinicalTrials.gov with IFOM ETS - The AIRC Institute of Molecular Oncology as lead sponsor.

NCT NCT05582538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel: The ATRiBRAVE Trial
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
December 15, 2022
Completion date
December 31, 2029
Enrollment
37 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer metastatic